Cancer Treatment
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Unlock global cancer treatment market insights. Stay ahead on drug approvals, clinical trials, and therapeutic advancements for pharma investors & BD.
Showing 1–4 of 4 articles
Quick answer
NovaPharmaNews Cancer Treatment hub for NMPA covers 4 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia
NMPA Priority Review Pathway: What You Need to Know About Innovative Drug Approvals
Antengene Presents Three Novel Cancer Programs at AACR 2026: Next-Generation ADC and TCE Therapies Show Promise
Antengene Presents Next-Generation ADC and AnTenGager TCE Programs at AACR 2026
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.